Gregor E Berger
Overview
Explore the profile of Gregor E Berger including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
47
Citations
1162
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Rice S, Nelson B, Amminger G, Francey S, Phillips L, Simmons M, et al.
Early Interv Psychiatry
. 2024 Apr;
18(10):859-868.
PMID: 38600049
Aim: Lithium, even at low doses, appears to offer neuroprotection against a wide variety of insults. In this controlled pilot, we examined the safety (i.e., side-effect profile) of lithium in...
2.
Wong B, Cross S, Zavaleta-Ramirez P, Bauda I, Hoffman P, Ibeziako P, et al.
J Am Acad Child Adolesc Psychiatry
. 2023 Feb;
62(9):998-1009.
PMID: 36806728
Objective: To compare psychiatric emergencies and self-harm at emergency departments (EDs) 1 year into the pandemic, to early pandemic and pre-pandemic, and to examine the changes in the characteristics of...
3.
Susai S, Healy C, Mongan D, Heurich M, Byrne J, Cannon M, et al.
Transl Psychiatry
. 2022 Oct;
12(1):454.
PMID: 36307392
Preliminary evidence indicates beneficial effects of omega-3 polyunsaturated fatty acids (PUFAs) in early psychosis. The present study investigates the molecular mechanism of omega-3 PUFA-associated therapeutic effects in clinical high-risk (CHR)...
4.
Cheng N, McLaverty A, Nelson B, Markulev C, Schafer M, Berger M, et al.
BJPsych Open
. 2022 Sep;
8(5):e165.
PMID: 36073014
Background: Cognitive impairments are well-established features of psychotic disorders and are present when individuals are at ultra-high risk for psychosis. However, few interventions target cognitive functioning in this population. Aims:...
5.
Susai S, Mongan D, Healy C, Cannon M, Cagney G, Wynne K, et al.
Brain Behav Immun
. 2022 Mar;
103:50-60.
PMID: 35341915
Background: Functional outcomes are important measures in the overall clinical course of psychosis and individuals at clinical high-risk (CHR), however, prediction of functional outcome remains difficult based on clinical information...
6.
Susai S, Mongan D, Healy C, Cannon M, Nelson B, Markulev C, et al.
Brain Behav Immun
. 2021 Oct;
99:147-156.
PMID: 34624483
There is increasing evidence that dysregulation of polyunsaturated fatty acids (FAs) mediated membrane function plays a role in the pathophysiology of schizophrenia. Even though preclinical findings have supported the anti-inflammatory...
7.
Kalkman H, Hersberger M, Walitza S, Berger G
Int J Mol Sci
. 2021 Apr;
22(9).
PMID: 33922396
Major depressive disorders (MDDs) are often associated with a deficiency in long-chain omega-3 polyunsaturated fatty acids (ω-3 PUFAs), as well as signs of low-grade inflammation. Epidemiological and dietary studies suggest...
8.
Berger M, Nelson B, Markulev C, Yuen H, Schafer M, Mossaheb N, et al.
Front Psychiatry
. 2020 Jun;
11:514.
PMID: 32595533
[This corrects the article DOI: 10.3389/fpsyt.2019.00393.].
9.
Hartmann J, Schmidt S, McGorry P, Berger M, Berger G, Chen E, et al.
Behav Res Ther
. 2019 Dec;
124:103527.
PMID: 31790853
The Ultra-High Risk (UHR) for psychosis group is known to be heterogeneous with diverse outcomes. This study aimed to: 1. Identify subclasses of UHR individuals based on trajectories of symptomatic...
10.
Amminger G, Nelson B, Markulev C, Yuen H, Schafer M, Berger M, et al.
Biol Psychiatry
. 2019 Nov;
87(3):243-252.
PMID: 31690495
Background: NEURAPRO was a multicenter, placebo-controlled trial of long-chain omega-3 polyunsaturated fatty acids (n-3 PUFAs) (fish oil) in 304 individuals at ultra-high risk for psychotic disorders. The study failed to...